Advanced NGS panel improves residual AML disease detection

OGT has launched the SureSeq Myeloid MRD Panel, a next-generation sequencing (NGS) assay designed for highly sensitive detection of measurable residual disease (MRD) biomarkers in acute myeloid leukemia (AML). This panel enhances the detection of ultra-low frequency variants, including large and complex FLT3 internal tandem duplications (ITDs), which are often missed by traditional PCR-based methods.

Accurate MRD detection is essential for improving clinical research and patient management in AML. Studies show that MRD negativity is linked to better long-term survival, making sensitive detection critical for understanding remission and relapse. The SureSeq panel targets 13 key AML biomarkers, expanding the ability to characterise the disease status with unprecedented resolution.

The panel’s hybrid capture technology delivers reliable detection of complex structural variants and avoids the inaccuracies common with PCR-based enrichment. OGT’s advanced bait design ensures robust identification of large FLT3-ITDs - up to 300 base pairs - providing insights that were previously difficult to obtain.

Designed with flexibility in mind, the SureSeq panel supports multiple pre-optimised workflows that can be tailored for sensitivity, sample batching, and sequencing needs. It includes complementary bioinformatics software, Interpret, which offers customisable analysis pipelines, reducing the bioinformatics burden for labs.

Researchers have praised the panel’s performance, noting its ability to detect all variants found by comparator assays plus additional clinically relevant mutations, enabling more comprehensive MRD analysis.

With expert support and streamlined workflows, OGT’s SureSeq Myeloid MRD Panel is positioned to advance AML clinical research and improve disease monitoring through precise, scalable genomic profiling.

More information online